In these experiments the MEK inhibition-dependent upregulation of MHC on tumours was further enhanced by immunotherapy dependent expression of IFN-γ, providing a mechanism by which combined therapy synergised to enhance T-cell responses. The gene discussed is IFNG; the disease is neoplasm.